Subscribe To

Price Alert Latest News Economic Calendar News

LLY / Eli Lilly expected to deliver a solid if unspectacular earnings update

Eli Lilly and Company is slated to unveil its second-quarter 2023 results on Tuesday (August), prior to the market opening, with Wall Street expecting earnings of $1.98 a share. That's up around 9% on the same period last year, and 15% ahead of the first quarter. Read More

Demo Live Account See Partner Details

Content Topics

Lilly

Expected

Deliver

Solid

Unspectacular

Earnings

Update

Stock

LLY

Posted: Aug 7 2023, 10:01

Author Name: Proactive Investors

LLY News

By The Motley Fool
November 3, 2023

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo No

By CNBC Television
November 2, 2023

Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham

Geoff Meacham, Bank of America senior pharmaceutical analyst, joins 'The Exchange' to discuss Eli Lilly's performance, the demand outlook for weight l

By Zacks Investment Research
November 2, 2023

Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be wor

By Yahoo Finance
November 2, 2023

Novo Nordisk, Eli Lilly stocks see boost on obesity drugs

Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozem

By The Motley Fool
November 2, 2023

Why Eli Lilly Stock Is Jumping Today

Lilly's Q3 revenue soared, but its earnings sank. However, the company's top- and bottom-line results handily beat Wall Street estimates.

By CNBC Television
November 2, 2023

Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook

CNBC's Joe Kernen reports on the company's quarterly earnings results.

By Barrons
November 2, 2023

Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically

Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.

By Market Watch
November 2, 2023

Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed

Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but sl

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.